PDX-Derived Gastric Cancer Organoid Model

Gastric cancer (GC), also called stomach cancer, is known as a highly heterogeneous malignant tumor. Despite constant drug studies, the disease is still prevalent worldwide and remains a high mortality. Patients with advanced GC are difficult to treat, and related clinical trials have a high failure rate, suggesting the necessity of developing novel preclinical models that can reflect in vivo drug responses more accurately. At Creative Biolabs, we possess a professional scientific team to study new 3D modeling technologies including PDX-derived GC organoids to serve our customers.

Construction of PDX-derived Gastric Cancer Organoid Models

Aside from GC patients, patient-derived xenografts (PDXs) are another tissue sample source for establishing GC organoids. Based on the existing PDX library, the tumor tissues are processed by mechanical dissociation and digestion by enzymes. Then they are expanded in a suitable medium to form the 3D structure of GC organoids. Generated PDX-derived organoids (PDXOs) can be used to establish the living biobank for various research purposes.

Fig 1. Schematic workflow of the establishment of PDXOs from PDX library.¹

Advantages of PDX-derived Gastric Cancer Organoid Models

At present, the PDXO technology is in a period of rapid development and displays many obvious advantages over conventional models in the GC research field. The PDX-derived GC organoid models provided by Creative Biolabs are high-quality and perform well in the following aspects.

• Maintain inherent attributes of the original tumor tissues and the corresponding PDXs.
• Show distinct advantages in characterizing the synergistic or antagonistic effects between different drugs.
• Possess a good engineer-ability, indicating it’s convenient to achieve gene editing which otherwise will be challenging in PDXs.
• Be capable of co-culturing with several components of the tumor microenvironment (TME), which facilitates the interaction investigation of tumors and TME.
• Easy to be established with high success rate when compared with PDXs,.

Applications

In pharmacology and translational research, PDXOs display their promising prospect as a complement model of PDXs and are considered to be a powerful platform for preclinical research. These models are dynamic for high-through screening and offer a new in vitro research tool for discovering new anti-tumor drug combinations. Furthermore, due to the high gene operability, such models enable broad applications, such as in vivo orthotropic imaging, tumor-associated antigen (TAA) expression and target validation.

Related Services

Creative Biolabs is very optimistic about the development of organoid technology. We have developed a variety of ex vivo organoid physiological models and will unswervingly focus on the 3D biology field in the future. To better meet our client's needs, we have launched multiple types of PDXOs and related technical services to enable the positve advancement of your preclinical drug development projects. Please contact us at any time to obtain more information or any support you want.

Related Sections:

• Patient-Derived Organoid (PDO) Model
• PDX-Derived Organoid (PDXO) Tumor Model